Olkem 40 H Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil 40 mg and Hydrochlorothiazide 12.5 mg. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby preventing vasoconstriction and aldosterone secretion, which results in vasodilation and reduced blood pressure. Hydrochlorothiazide is a thiazide diuretic that promotes sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to decreased plasma volume and blood pressure. The combination of these two agents provides complementary mechanisms to effectively manage hypertension, especially in patients who do not achieve adequate blood pressure control with monotherapy. Olkem 40 H is indicated for the treatment of essential hypertension and may reduce the risk of cardiovascular events associated with high blood pressure. It should be used under medical supervision with appropriate monitoring of renal function, electrolytes, and blood pressure. Caution is advised in patients with impaired renal or hepatic function, electrolyte imbalances, or hypersensitivity to sulfonamides. Common adverse effects may include dizziness, hypotension, hyperkalemia, or electrolyte disturbances. Patient adherence to prescribed dosage and lifestyle modifications is essential for optimal therapeutic outcomes.